Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing email@example.com or calling +44 (0)1707 367554.
For over 15 years, there have been limited advances in adjuvant systemic therapies for early-stage NSCLC3
- Lung cancer remains one of the most prevalent forms of cancer in the UK, with approximately 52,000 cases in 20204
- Unfortunately, NSCLC is associated with poor overall survival, even for those diagnosed early5,6
- In the early setting, preventing recurrence is key as most of the mortality in postresectional NSCLC is related to recurrence5
- Surgery is the cornerstone of treatment3,7,8 and for those who are fit enough, adjuvant chemotherapy can further reduce patients’ risk of recurrence9
- However, for many patients it is not enough5,6 – the International Adjuvant Lung Cancer Trial showed that at 5 years, approximately 60% of patients with stage I-III NSCLC saw their disease return6
DFS in the International Adjuvant Lung Cancer Trial6
Adapted from Arriagada6
Now though, adjuvant TECENTRIQ may allow more eligible patients to live free of disease recurrence than the current standard of care2
- TECENTRIQ is the first immunotherapy licensed for use in adult patients with stage II to IIIA (7th edition of the UICC/AJCC-staging system) NSCLC and PD-L1 expression on ≥50% of tumour cells1,2
- After complete resection and 1–4 cycles of platinum-based chemotherapy, TECENTRIQ may improve DFS and reduce eligible patients’ risk of recurrence vs active monitoring2
AJCC, American Joint Committee on Cancer; DFS, disease-free survival; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; TC, tumour cell; UICC, Union for International Cancer Control.
- TECENTRIQ GB Summary of Product Characteristics.
- Felip E et al. Lancet 2021; 398(10308): 1344–1357.
- Vansteenkiste J et al. Ann Oncol 2019; 30(8): 1244–1253.
- International Agency for Research on Cancer. United Kingdom. Globocan 2020. Available at: https://gco.iarc.fr/today/data/factsheets/populations/826-united-kingdom-fact-sheets.pdf accessed January 2022.
- Taylor MD et al. Ann Thorac Surg 2012; 93(6): 1813–1821.
- Arriagada R et al. J Clin Oncol 2010; 28(1): 35–42.
- Postmus PE et al. Ann Oncol 2017; 28(suppl 4): iv1–iv21.
- NICE Pathways. Non-small-cell lung cancer: treatments with curative intent. July 2021.
- Burdett S et al. Cochrane Database Syst Rev 2015; (3): CD011430.
Date of preparation: February 2022.